Boston Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Boston Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.92M	Buy	69,935 +24,112	+53%	+$714K	0.1%	256
2019 Q2	$1.52M	Sell	45,823 -8,966	-16%	-$307K	0.08%	264
2019 Q1	$1.92M	Buy	54,789 +4,496	+9%	+$167K	0.1%	235
2018 Q4	$1.67M	Sell	50,293 -76,545	-60%	-$3.29M	0.1%	236
2018 Q3	$6.39M	Buy	126,838 +3,637	+3%	+$180K	0.28%	102
2018 Q2	$7.37M	Sell	123,201 -1,938	-2%	-$100K	0.18%	105
2018 Q1	$5.73M	Buy	+125,139	New	+$5.22M	0.15%	149

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Boston Advisors's SUPN Position: Q3 2019 in Review

Boston Advisors increased its Supernus Pharmaceuticals (SUPN) stake by 53% in Q3 2019, buying an estimated $714K and bringing the position to 69,935 shares worth $1.92M. The position accounts for 0.1% of the portfolio, ranked #256.

Boston Advisors first reported a position in SUPN in Q1 2018 and has held it in 7 quarters since. The position peaked at $7.37M in Q2 2018. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

Boston Advisors held 69,935 shares of Supernus Pharmaceuticals worth $1.92M as of Q3 2019.
Boston Advisors bought 24,112 Supernus Pharmaceuticals shares in Q3 2019, an estimated $714K.
Supernus Pharmaceuticals made up 0.1% of Boston Advisors's portfolio in Q3 2019, its #256 holding.
Boston Advisors first reported a position in Supernus Pharmaceuticals in Q1 2018 and has held it in 7 quarters since.
Boston Advisors's Supernus Pharmaceuticals position peaked at $7.37M in Q2 2018.
243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.